In the News

Research advances from the National Institutes of Health (NIH) Intramural Research Program (IRP) often make headlines. Read the news releases that describe our most recent findings:

Featured Article

Here’s when your weight loss will plateau, according to science

CNN
Monday, April 22, 2024

Whether you’re shedding pounds with the help of effective new medicines, slimming down after weight loss surgery or cutting calories and adding exercise, there will come a day when the numbers on the scale stop going down, and you hit the dreaded weight loss plateau.

In a recent study, Kevin Hall, a researcher at the National Institutes of Health who specializes in measuring metabolism and weight change, looked at when weight loss typically stops depending on the method people were using to drop pounds. He broke down the plateau into mathematical models using data from high-quality clinical trials of different ways to lose weight to understand why people stop losing when they do. The study published Monday in the journal Obesity.

First drug candidate from NIH program acquired by biopharmaceutical company

Potential treatment targets sickle cell disease

A drug candidate developed by researchers at the NIH’s National Center for Advancing Translational Sciences (NCATS) and its collaborators to treat sickle cell disease has been acquired by Baxter International’s BioScience business. The drug candidate, Aes-103, is the first specifically developed to target the underlying molecular mechanism of sickle cell disease. Baxter now will advance the clinical development activities required for regulatory approval and commercialization.

Low doses of arsenic cause cancer in male mice

Mice exposed to low doses of arsenic in drinking water, similar to what some people might consume, developed lung cancer, researchers at the National Institutes of Health have found.

Low doses of arsenic cause cancer in male mice

NIH study finds extreme obesity may shorten life expectancy up to 14 years

Adults with extreme obesity have increased risks of dying at a young age from cancer and many other causes including heart disease, stroke, diabetes, and kidney and liver diseases, according to results of an analysis of data pooled from 20 large studies of people from three countries. The study, led by researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, found that people with class III (or extreme) obesity had a dramatic reduction in life expectancy compared with people of normal weight. The findings appeared July 8, 2014, in PLOS Medicine.

Acute kidney injury, chronic kidney disease each a risk of the other

NIH study suggests people with either should be monitored for both

Acute kidney injury (AKI) and chronic kidney disease (CKD) are closely intertwined, with each disease a risk factor for developing the other and sharing other risk factors in common, as well as sharing causes for the diseases to get worse, and outcomes, suggests a comprehensive analysis by scientists at the National Institutes of Health and George Washington University Medical Center, Washington, D.C.

NIH study reveals gene critical to the early development of cilia

Cilia are key to a broad class of genetic disorders

Researchers at the National Eye Institute (NEI) have described the functions of a gene responsible for anchoring cilia – sensory hair-like extensions present on almost every cell of the body. They show in a mouse model that without the gene Cc2d2a, cilia throughout the body failed to grow, and the mice died during the embryonic stage. The finding adds to an expanding body of knowledge about ciliopathies, a class of genetic disorders that result from defects in the structure or function of cilia. NEI is part of the National Institutes of Health.

NIH study reveals gene critical to the early development of cilia

Adults stop anti-rejection drugs after partial stem-cell transplant reverses sickle cell disease

NIH trial success suggests a new treatment option for older, sicker patients

Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of the Journal of the American Medical Association. The trial was conducted at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, by researchers from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute (NHLBI).

Adults stop anti-rejection drugs after partial stem-cell transplant reverses sickle cell disease

New report offers a primer for doctors’ use of clinical genome and exome sequencing

Sooner than almost anyone expected, a new, genome-based technology for demystifying undiagnosed illnesses — particularly rare childhood diseases — is moving from research laboratories into general medical practice. Now, two leading scientists have sketched out what doctors need to know in order to use the new technology effectively.

NIH launches 3D print exchange for researchers, students

Public website promotes health and science applications of 3D printing

The National Institutes of Health has launched the NIH 3D Print Exchange, a public website that enables users to share, download and edit 3D print files related to health and science. These files can be used, for example, to print custom laboratory equipment and models of bacteria and human anatomy.

NIH scientists take totally tubular journey through brain cells

Study may advance understanding of how brain cell tubes are modified under normal and disease conditions

In a new study, scientists at the National Institutes of Health took a molecular-level journey into microtubules, the hollow cylinders inside brain cells that act as skeletons and internal highways. They watched how a protein called tubulin acetyltransferase (TAT) labels the inside of microtubules. The results, published in Cell, answer long-standing questions about how TAT tagging works and offer clues as to why it is important for brain health.

Hormone treatment restores bone density for young women with menopause-like condition

NIH study reveals way to improve bone health for young women with POI

Researchers have found that hormone replacement therapy in young women with primary ovarian insufficiency (POI) led to increases in their bone mineral density, restoring levels to normal. The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health.

Hormone treatment restores bone density for young women with menopause-like condition

Continue Exploring the IRP

This page was last updated on Monday, April 22, 2024